291 related articles for article (PubMed ID: 23048078)
1. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
[TBL] [Abstract][Full Text] [Related]
2. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
Adams S; Kozhaya L; Martiniuk F; Meng TC; Chiriboga L; Liebes L; Hochman T; Shuman N; Axelrod D; Speyer J; Novik Y; Tiersten A; Goldberg JD; Formenti SC; Bhardwaj N; Unutmaz D; Demaria S
Clin Cancer Res; 2012 Dec; 18(24):6748-57. PubMed ID: 22767669
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer treatment with imiquimod: applying an old lotion to a new disease.
Kohrt H
Clin Cancer Res; 2012 Dec; 18(24):6571-3. PubMed ID: 23172886
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
Lu H; Wagner WM; Gad E; Yang Y; Duan H; Amon LM; Van Denend N; Larson ER; Chang A; Tufvesson H; Disis ML
J Immunol; 2010 May; 184(9):5360-7. PubMed ID: 20308630
[TBL] [Abstract][Full Text] [Related]
6. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
7. Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Salazar LG; Lu H; Reichow JL; Childs JS; Coveler AL; Higgins DM; Waisman J; Allison KH; Dang Y; Disis ML
JAMA Oncol; 2017 Jul; 3(7):969-973. PubMed ID: 28114604
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
[TBL] [Abstract][Full Text] [Related]
10. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
11. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Bellmann L; Cappellano G; Schachtl-Riess JF; Prokopi A; Seretis A; Ortner D; Tripp CH; Brinckerhoff CE; Mullins DW; Stoitzner P
Int J Cancer; 2020 Mar; 146(5):1409-1420. PubMed ID: 31702822
[TBL] [Abstract][Full Text] [Related]
12. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
13. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
14. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.
Ondo AL; Mings SM; Pestak RM; Shanler SD
J Am Acad Dermatol; 2006 Dec; 55(6):1092-4. PubMed ID: 17097406
[TBL] [Abstract][Full Text] [Related]
15. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
17. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulation by imiquimod in patients with high-risk primary melanoma.
Narayan R; Nguyen H; Bentow JJ; Moy L; Lee DK; Greger S; Haskell J; Vanchinathan V; Chang PL; Tsui S; Konishi T; Comin-Anduix B; Dauphine C; Vargas HI; Economou JS; Ribas A; Bruhn KW; Craft N
J Invest Dermatol; 2012 Jan; 132(1):163-9. PubMed ID: 21850019
[TBL] [Abstract][Full Text] [Related]
19. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
20. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
